

05 FEB 22 AM 10:1

Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510
---	--

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Steve Giuli			
2. Address <input type="checkbox"/> Check if different than previously reported 1725 1st. NW Ste. 300			
3. Principal Place of Business (if different from line 2) City: Washington State/zip (or Country) DC 20006			
4. Contact Name Steve Giuli		Telephone 202-349-3790	E-mail (optional)
			5. Senate ID # 89190
7. Client Name <input checked="" type="checkbox"/> Self Alpharma, US Human Pharmaceuticals			6. House ID #

TYPE OF REPORT 8. Year 2004 Midyear (January 1-June 30) OR Year End (July 1-December)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇌ Termination Date _____

11. No Lobbying A

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13	
<p>12. Lobbying Firms</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input type="checkbox"/> ⇌ \$ _____ Income (nearest \$20,000)</p> <p>Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSES relating to lobbying activities for this reporting period were:</p> <p>Less than \$10,000 <input type="checkbox"/></p> <p>\$10,000 or more <input checked="" type="checkbox"/> ⇌ \$ <u>81,500</u> Expenses (nearest \$20,000)</p> <p>14. REPORTING METHOD. Check box to indicate expert accounting method. See instructions for description of option</p> <p><input type="checkbox"/> Method A. Reporting amounts using LDA definitions</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b) Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) Internal Revenue Code</p>

Signature Steven Giuli Date 2/11/05

Printed Name and Title Steven Giuli, Director of Legislative Affairs

Registrant Name Steve Giuli Client Name Alpharma, US Human Pharms.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reg engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code _____ (one per page) MMM, TAX, PHA, HCR, MED

16. Specific lobbying issues
See Attached Sheets.

17. House(s) of Congress and Federal agencies contacted Check if None
US House of Representatives
US Senate
Food & Drug Administration
Centers For Medicare & Medicaid Services

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<u>Steven Giuli</u>	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature Steven Giuli Date 2/11/05
Printed Name and Title Steven Giuli, Director of Legislative Affairs

MMM

1. Medicare Modernization Act, PL 108-173
 - a. Title XI Access to Affordable Pharmaceuticals
2. Medicaid Pharmaceutical Rebates, No Specific Legislation

TAX

1. S 1637, Jumpstart Our Business Through Strength Act
 - a. Section 231/965, Toll Tax on Excess Qualified Foreign Distribution Amount
 - b. S AMDT 3117 to S 1637
2. HR 4520. American Jobs Creation Act of 2004
 - a. Section 271. Incentives to Reinvest Foreign Earnings in the United States

PHA

1. S. 2137, Pharmaceutical Market Access Act of 2003, Entire Bill
2. S. 2328, Pharmaceutical Market Access & Drug Safety Act of 2004, Entire Bill
3. S. 2493, Safe Import Act of 2004, Entire Bill
4. HR 3880, Internet Pharmacy Consumer Protection Act of 2004, Entire Bill
5. FDA Docket 2004N-0087, Generic Drug Issues
6. Generic Biologic Issues, No Specific Legislation
7. "Authorized" Generic Pharmaceuticals, No Specific Legislation

MED

1. S. 666, The Biological, Chemical, and Radiological Weapons Countermeasures Research Act, Entire Bill
-

HCR

1. HR 5, the Help, Efficient, Accessible, Low-cost, Timely, Healthcare Act of 2003, Section 7(e), No Civil Penalties for Products in Compliance with FDA Standards
 2. S.11, Patients First Act of 2003, Section 7(e), No Civil Penalties for Products in Compliance with FDA Standards
-

